Status:

COMPLETED

Biomarkers in Patients With Head and Neck Cancer

Lead Sponsor:

ECOG-ACRIN Cancer Research Group

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18-120 years

Brief Summary

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer...

Detailed Description

OBJECTIVES: * To determine the mutation rates of HRAS and PIK3CA in patients with head and neck squamous cell carcinoma (HNSCC) who were treated with cisplatin/placebo and cisplatin/cetuximab on prot...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Treated on protocol ECOG-E5397
  • PATIENT CHARACTERISTICS:
  • Not specified
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics

Exclusion

    Key Trial Info

    Start Date :

    November 21 2011

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2012

    Estimated Enrollment :

    70 Patients enrolled

    Trial Details

    Trial ID

    NCT01466257

    Start Date

    November 21 2011

    End Date

    January 1 2012

    Last Update

    May 19 2017

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Biomarkers in Patients With Head and Neck Cancer | DecenTrialz